Skip to main content
Clinical Trials/NCT05455944
NCT05455944
Completed
N/A

Analgesic Efficacy of Pre-operative Oral Pregabalin in Dacryocystorhinostomy Surgery

Sameh Fathy1 site in 1 country100 target enrollmentJanuary 1, 2020

Overview

Phase
N/A
Intervention
Placebo
Conditions
Dacryocystitis
Sponsor
Sameh Fathy
Enrollment
100
Locations
1
Primary Endpoint
Changes in pain scores by visual analogue scale (VAS)
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This study is conducted to evaluate the effects of preoperative oral pregabalin on postoperative pain and analgesic requirements in patients undergoing DCR surgery. The primary outcome is to compare pain scores by visual analogue scale (VAS). Secondary outcomes are the time of first analgesic request, the total analgesic requirements during the postoperative 24 hours, the incidence of PONV, in addition to effect on hemodynamic parameters between the two groups.

Detailed Description

External dacryocystorhinostomy (DCR) is still considered the golden standard for lacrimal surgery. It is a bypass technique which creates an anastomosis between the lacrimal sac and the nasal mucosa through a bony ostium via an external skin incision. External DCR can be completed under either local or general anesthesia. It is a painful surgical procedure that involves intra- and extra-ocular dissection, with a high prevalence post-operative nausea and vomiting (PONV). So, it is necessary to ensure a stress-free peri-operative period with adequate pain relief and a low incidence of PONV after DCR surgery. Pregabalin is a lipophilic gamma-amino-butyric acid (GABA) analogue that binds to the voltage-gated calcium channels. It reduces the excitability of the dorsal horn neurons after tissue damage. It has anticonvulsant, anxiolytic and sleep-modulating properties. It was shown to be effective in several models of neuropathic pain, incisional injury, and inflammatory injury. Preoperative administration of pregabalin is supposed to be a promising technique of enhancing postoperative pain control and reduction in postoperative opioid consumption. This study is a prospective randomized double-blind clinical trial included 100 ASA I and II patients of both sex with age between 18 and 65 years old, who are planned for elective DCR surgery under general anesthesia in Mansoura University ophthalmology center. Informed written consent is obtained from all subjects in the study after ensuring confidentiality. Details of the anesthetic technique and the study protocol are clarified to the entire involved cases. Patients are randomly assigned to two equal groups according to computer-generated randomization schedule. A prospective analysis of the collected data is performed using the Statistical Package for the Social Sciences (SPSS) program for Windows (version 22). All data are considered statistically significant if P value is ≤ 0.05.

Registry
clinicaltrials.gov
Start Date
January 1, 2020
End Date
December 30, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

Sameh Fathy

Lecturer of anesthesia, ICU & pain management - Faculty of Medicine

Mansoura University

Eligibility Criteria

Inclusion Criteria

  • American Society of Anesthesiology (ASA) I and II patients.
  • Scheduled for DCR surgery.

Exclusion Criteria

  • Patient' refusal of consent.
  • Mental, psychological or neurological disorders.
  • Patients with history of drug or alcohol abuse.
  • History of know sensitivity to the used drugs.
  • Bleeding or coagulation diathesis.
  • Obese patients (body mass index (BMI) \< 35).
  • Pregnancy and lactation.

Arms & Interventions

Control Group

Patients received two capsules: one at the night of surgery, and the other at 2 hours before the surgery

Intervention: Placebo

Pregabalin Group

Patients received two capsules: one at the night of surgery, and the other at 2 hours before the surgery

Intervention: Pregabalin 150mg

Outcomes

Primary Outcomes

Changes in pain scores by visual analogue scale (VAS)

Time Frame: Up to 24 hours after the procedure

Pain (VAS) score from 0 to 10 (0 = no pain and 10 = the worst imaginable pain)

Secondary Outcomes

  • Changes in heart rate(Up to the end of the surgery)
  • Changes in mean arterial blood pressure(Up to the end of the surgery)
  • First analgesic request(Up to 24 hours after the procedure)
  • Total analgesic requirements of pethidine(Up to 24 hours after the procedure)
  • Incidence of postoperative nausea and vomiting(Up to 24 hours after the procedure)

Study Sites (1)

Loading locations...

Similar Trials